Tag Archives: Immuno-Oncology

December, 2018

  • 20 December

    Gilead and Agenus Partner for Development of Immuno-Oncology Therapies

    FOSTER CITY, Calif. & LEXINGTON, Mass.–(BUSINESS WIRE)–Gilead Sciences, Inc. (NASDAQ: GILD) and Agenus Inc. (NASDAQ: AGEN) announced today the companies have entered into an immuno-oncology (I-O) partnership focused on the development and commercialization of up to five novel immuno-oncology therapies. Under the terms of the agreement, Agenus will receive $150 …

November, 2018

September, 2018

August, 2018

  • 22 August

    AbbVie Exercises Option to License Argenx’s GARP Checkpoint Inhibitor

    Breda, the Netherlands/Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced the exercise by AbbVie of its exclusive license option to develop and commercialize ARGX-115, an antibody targeting the …